ArticleMethods in molecular biology (Clifton, N.J.)2016
Mesenchymal Stem Cells in Cardiology.
Article in Methods in molecular biology (Clifton, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Exploring mesenchymal stem cells as a novel therapeutic approach for HACEK endocarditis: a narrative review.Journal of cardiothoracic surgery · 2026Review
- VEGF-B is a novel mediator of ER stress which induces cardiac angiogenesis via RGD-binding integrins independent of VEGFR1/NRP activities.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- 3D Culture of MSCs for Clinical Application.Bioengineering (Basel, Switzerland) · 2024Review
- Research hotspots and emerging trends of mesenchymal stem cells in cardiovascular diseases: a bibliometric-based visual analysis.Frontiers in cardiovascular medicine · 2024Article
- Hypoxia and inflammatory factor preconditioning enhances the immunosuppressive properties of human umbilical cord mesenchymal stem cells.World journal of stem cells · 2023Article
- Therapeutic potential of mesenchymal stromal/stem cells in critical-care patients with systemic inflammatory response syndrome.Clinical and translational medicine · 2023Review
- Mechanotransduction of mesenchymal stem cells (MSCs) during cardiomyocytes differentiation.Heliyon · 2022Review
- Mechanotransduction in Mesenchymal Stem Cells (MSCs) Differentiation: A Review.International journal of molecular sciences · 2022Review
- Bone Marrow Mesenchymal Stem Cells and Their Derived Extracellular Vesicles Attenuate Non-Alcoholic Steatohepatitis-Induced Cardiotoxicity via Modulating Cardiac Mechanisms.Life (Basel, Switzerland) · 2022Article
- Bidirectional relationship between cardiac extracellular matrix and cardiac cells in ischemic heart disease.Stem cells (Dayton, Ohio) · 2021Review
- Mitochondrial Quality Control in Cardiac-Conditioning Strategies against Ischemia-Reperfusion Injury.Life (Basel, Switzerland) · 2021Review
- CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development.Journal of personalized medicine · 2021Review
- Stem Cell-Derived Exosomes Potential Therapeutic Roles in Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2021Review
- A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia.Frontiers in pediatrics · 2021Review
- Functions of Mesenchymal Stem Cells in Cardiac Repair.Advances in experimental medicine and biology · 2021Article
- The role of regenerative therapy in the treatment of right ventricular failure: a literature review.Stem cell research & therapy · 2020Review
- Differences in Mitochondrial Membrane Potential Identify Distinct Populations of Human Cardiac Mesenchymal Progenitor Cells.International journal of molecular sciences · 2020Article
- Adipose-Derived Mesenchymal Stem Cells and Conditioned Medium Attenuate the Memory Retrieval Impairment During Sepsis in Rats.Molecular neurobiology · 2020Article
- Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy.Cellular and molecular life sciences : CMLS · 2020Review
- Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.Journal of translational medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cardiovascular disease (CVD) accounts for more deaths globally than any other single disease. There are on average 1.5 million episodes of myocardial infarction (heart attack) each year in the United States alone with roughly one-third resulting in death. There is therefore a major need for developing new and effective strategies to promote cardiac repair. Intramyocardial transplantation of mesenchymal stem cells (MSCs) has emerged as a leading contender in the pursuit of clinical intervention and therapy. MSCs are potent mediators of cardiac repair and are therefore an attractive tool in the development of preclinical and clinical trials. MSCs are capable of secreting a large array of soluble factors, which have had demonstrated effects on pathogenic cardiac remolding, fibrosis, immune activation, and cardiac stem cell proliferation within the damaged heart. MSCs are also capable of differentiation into cardiomyocytes, endothelial cells, and vascular smooth muscle cells, although the relative contribution of trilineage differentiation and paracrine effectors on cardiac repair remains the subject of active investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.